Skip to main content

$1.035 (0%)

High

-

Low

-

Trades

-

Turnover

$0

Volume

0
3 July 2025 at 5:19pm
Register to track BD1 and receive email alerts.
Subject
BD1 Ann: BARD1 Files Two New Patents Protecting SubB2M & EXO-NET

BD1 Ann: BARD1 EXO-NET Exosome Data Presented at ISEV2021 Conference

BD1 Ann: BARD1 Launches its RUO EXO-NET Product

BD1 Ann: Appendix 4C and Quarterly Activities Report

BD1 Ann: Positive Results from the BARD1 Autoantibody Assay

BD1 Ann: Appendix 3G - Long Term Incentive Options Issued to CEO

BD1 Ann: BARD1 Signs Option Agreement for Type 3C Diabetes Test

BD1 Ann: Appendix 2A

BD1 Ann: Positive Results Evaluation of EXO-NET in Pancreatic Cancer

BD1 Ann: Appendix 2A

BD1 Ann: Australian Patent Granted for hTERT

BD1 Ann: BARD1 Achieves hTERT Registration and First Order in Korea

BD1 Ann: Appendix 2A

BD1 Ann: Change in substantial holding

BD1 Ann: Ceasing to be a substantial holder

BD1 Ann: Appendix 4D and Half-year financial report

BD1 Ann: Commencement of Legal Proceedings Against BARD1

BD1 Ann: Appendix 2A

BD1 Ann: Ceasing to be a substantial holder

BD1 Ann: Becoming a substantial holder

BD1 Ann: Excellent SubB2M Breast Cancer Test Data

BD1 Ann: Outstanding SubB2M Ovarian Cancer Test Data

BD1 Ann: Change of Auditor

BD1 Ann: Appendix 4C & Quarterly Activities Report

BD1 Ann: U.S. Patent Granted for NET Technology for Exosome Capture

BD1 Ann: Final Director's Interest Notice - Dr Irminger-Finger

BD1 Ann: Dr Irminger steps down from Board, continues as Consultant

BD1 Ann: Change of Director's Interest Notice - Cumming

BD1 Ann: Change of Director's Interest Notice - Powell

BD1 Ann: Change of Director's Interest Notice - Johnston

BD1 Ann: Final Director's Interest Notice - Helen Fisher

BD1 Ann: Patent Granted in China for hTERT

BD1 Ann: Further Detail on BARD1's US Sales Strategy

BD1 Ann: Trading Halt

BD1 Ann: Pause in Trading

BD1 Ann: Results of Meeting

BD1 Ann: AGM & CEO Presentations and Chairman's Transcript

BD1 Ann: Consolidation/Split - BD1

BD1 Ann: Helen Fisher Steps Down from BARD1 Board

BD1 Ann: BARD1 Gains New High-volume Customer for its hTERT Test

BD1 Ann: Appendix 4C and Quarterly Activities Report

BD1 Ann: Notice of Annual General Meeting/Proxy Form

BD1 Ann: Notice of AGM ASX Listing Rule 3.13.1

Register to track BD1 and receive email alerts.

Similar Companies

AHX
CAJ
HLA
HLS
IDX
RHY
SHL
SLA
TTB